NEW YORK – Oncocyte said Thursday that it has entered a distribution agreement with CORE Diagnostics to expand the commercial availability of its DetermaRx test to India, the Middle East, and Africa.
DetermaRx is Oncocyte’s first commercially launched assay and was initially called the Razor Genomic test when Oncocyte acquired Razor and it's IP last year.